View in EDS

Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial.

Saved in:
Bibliographic Details
Title: Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial.
Authors: Gillison, Maura L., Ringash, Jolie, Galvin, James, Min Yao, Koyfman, Shlomo A., Blakaj, Dukagjin M., Razaq, Mohammed A., Colevas, A. Dimitrios, Quynh Thu Le, Beitler, Jonathan J., Jones, Christopher U., Dunlap, Neal E., Trotti, Andy M., Seaward, Samantha A., Spencer, Sharon, Galloway, Thomas J., Phan, Jack, Yao, Min, Le, Quynh Thu, Harris, Jonathan
Source: Lancet. 1/5/2019, Vol. 393 Issue 10166, p40-50. 11p.
Subjects: Antineoplastic agents, Cisplatin, Comparative studies, Drug administration, Research methodology, Medical cooperation, Papillomavirus diseases, Radiotherapy, Research, Research funding, Evaluation research, Treatment effectiveness, Kaplan-Meier estimator, Oropharyngeal cancer, Disease complications
Abstract: Background: Patients with human papillomavirus (HPV)-positive oropharyngeal squamous cell carcinoma have high survival when treated with radiotherapy plus cisplatin. Whether replacement of cisplatin with cetuximab-an antibody against the epidermal growth factor receptor-can preserve high survival and reduce treatment toxicity is unknown. We investigated whether cetuximab would maintain a high proportion of patient survival and reduce acute and late toxicity.Methods: RTOG 1016 was a randomised, multicentre, non-inferiority trial at 182 health-care centres in the USA and Canada. Eligibility criteria included histologically confirmed HPV-positive oropharyngeal carcinoma; American Joint Committee on Cancer 7th edition clinical categories T1-T2, N2a-N3 M0 or T3-T4, N0-N3 M0; Zubrod performance status 0 or 1; age at least 18 years; and adequate bone marrow, hepatic, and renal function. We randomly assigned patients (1:1) to receive either radiotherapy plus cetuximab or radiotherapy plus cisplatin. Randomisation was balanced by using randomly permuted blocks, and patients were stratified by T category (T1-T2 vs T3-T4), N category (N0-N2a vs N2b-N3), Zubrod performance status (0 vs 1), and tobacco smoking history (≤10 pack-years vs >10 pack-years). Patients were assigned to receive either intravenous cetuximab at a loading dose of 400 mg/m2 5-7 days before radiotherapy initiation, followed by cetuximab 250 mg/m2 weekly for seven doses (total 2150 mg/m2), or cisplatin 100 mg/m2 on days 1 and 22 of radiotherapy (total 200 mg/m2). All patients received accelerated intensity-modulated radiotherapy delivered at 70 Gy in 35 fractions over 6 weeks at six fractions per week (with two fractions given on one day, at least 6 h apart). The primary endpoint was overall survival, defined as time from randomisation to death from any cause, with non-inferiority margin 1·45. Primary analysis was based on the modified intention-to-treat approach, whereby all patients meeting eligibility criteria are included. This study is registered with ClinicalTrials.gov, number NCT01302834.Findings: Between June 9, 2011, and July 31, 2014, 987 patients were enrolled, of whom 849 were randomly assigned to receive radiotherapy plus cetuximab (n=425) or radiotherapy plus cisplatin (n=424). 399 patients assigned to receive cetuximab and 406 patients assigned to receive cisplatin were subsequently eligible. After median follow-up duration of 4·5 years, radiotherapy plus cetuximab did not meet the non-inferiority criteria for overall survival (hazard ratio [HR] 1·45, one-sided 95% upper CI 1·94; p=0·5056 for non-inferiority; one-sided log-rank p=0·0163). Estimated 5-year overall survival was 77·9% (95% CI 73·4-82·5) in the cetuximab group versus 84·6% (80·6-88·6) in the cisplatin group. Progression-free survival was significantly lower in the cetuximab group compared with the cisplatin group (HR 1·72, 95% CI 1·29-2·29; p=0·0002; 5-year progression-free survival 67·3%, 95% CI 62·4-72·2 vs 78·4%, 73·8-83·0), and locoregional failure was significantly higher in the cetuximab group compared with the cisplatin group (HR 2·05, 95% CI 1·35-3·10; 5-year proportions 17·3%, 95% CI 13·7-21·4 vs 9·9%, 6·9-13·6). Proportions of acute moderate to severe toxicity (77·4%, 95% CI 73·0-81·5 vs 81·7%, 77·5-85·3; p=0·1586) and late moderate to severe toxicity (16·5%, 95% CI 12·9-20·7 vs 20·4%, 16·4-24·8; p=0·1904) were similar between the cetuximab and cisplatin groups.Interpretation: For patients with HPV-positive oropharyngeal carcinoma, radiotherapy plus cetuximab showed inferior overall survival and progression-free survival compared with radiotherapy plus cisplatin. Radiotherapy plus cisplatin is the standard of care for eligible patients with HPV-positive oropharyngeal carcinoma.Funding: National Cancer Institute USA, Eli Lilly, and The Oral Cancer Foundation. [ABSTRACT FROM AUTHOR]
Copyright of Lancet is the property of Lancet and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
FullText Text:
  Availability: 0
Header DbId: pbh
DbLabel: Psychology and Behavioral Sciences Collection
An: 134093538
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Gillison%2C+Maura+L%2E%22">Gillison, Maura L.</searchLink><br /><searchLink fieldCode="AR" term="%22Ringash%2C+Jolie%22">Ringash, Jolie</searchLink><br /><searchLink fieldCode="AR" term="%22Galvin%2C+James%22">Galvin, James</searchLink><br /><searchLink fieldCode="AR" term="%22Min+Yao%22">Min Yao</searchLink><br /><searchLink fieldCode="AR" term="%22Koyfman%2C+Shlomo+A%2E%22">Koyfman, Shlomo A.</searchLink><br /><searchLink fieldCode="AR" term="%22Blakaj%2C+Dukagjin+M%2E%22">Blakaj, Dukagjin M.</searchLink><br /><searchLink fieldCode="AR" term="%22Razaq%2C+Mohammed+A%2E%22">Razaq, Mohammed A.</searchLink><br /><searchLink fieldCode="AR" term="%22Colevas%2C+A%2E+Dimitrios%22">Colevas, A. Dimitrios</searchLink><br /><searchLink fieldCode="AR" term="%22Quynh+Thu+Le%22">Quynh Thu Le</searchLink><br /><searchLink fieldCode="AR" term="%22Beitler%2C+Jonathan+J%2E%22">Beitler, Jonathan J.</searchLink><br /><searchLink fieldCode="AR" term="%22Jones%2C+Christopher+U%2E%22">Jones, Christopher U.</searchLink><br /><searchLink fieldCode="AR" term="%22Dunlap%2C+Neal+E%2E%22">Dunlap, Neal E.</searchLink><br /><searchLink fieldCode="AR" term="%22Trotti%2C+Andy+M%2E%22">Trotti, Andy M.</searchLink><br /><searchLink fieldCode="AR" term="%22Seaward%2C+Samantha+A%2E%22">Seaward, Samantha A.</searchLink><br /><searchLink fieldCode="AR" term="%22Spencer%2C+Sharon%22">Spencer, Sharon</searchLink><br /><searchLink fieldCode="AR" term="%22Galloway%2C+Thomas+J%2E%22">Galloway, Thomas J.</searchLink><br /><searchLink fieldCode="AR" term="%22Phan%2C+Jack%22">Phan, Jack</searchLink><br /><searchLink fieldCode="AR" term="%22Yao%2C+Min%22">Yao, Min</searchLink><br /><searchLink fieldCode="AR" term="%22Le%2C+Quynh+Thu%22">Le, Quynh Thu</searchLink><br /><searchLink fieldCode="AR" term="%22Harris%2C+Jonathan%22">Harris, Jonathan</searchLink>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Lancet%22">Lancet</searchLink>. 1/5/2019, Vol. 393 Issue 10166, p40-50. 11p.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22Antineoplastic+agents%22">Antineoplastic agents</searchLink><br /><searchLink fieldCode="DE" term="%22Cisplatin%22">Cisplatin</searchLink><br /><searchLink fieldCode="DE" term="%22Comparative+studies%22">Comparative studies</searchLink><br /><searchLink fieldCode="DE" term="%22Drug+administration%22">Drug administration</searchLink><br /><searchLink fieldCode="DE" term="%22Research+methodology%22">Research methodology</searchLink><br /><searchLink fieldCode="DE" term="%22Medical+cooperation%22">Medical cooperation</searchLink><br /><searchLink fieldCode="DE" term="%22Papillomavirus+diseases%22">Papillomavirus diseases</searchLink><br /><searchLink fieldCode="DE" term="%22Radiotherapy%22">Radiotherapy</searchLink><br /><searchLink fieldCode="DE" term="%22Research%22">Research</searchLink><br /><searchLink fieldCode="DE" term="%22Research+funding%22">Research funding</searchLink><br /><searchLink fieldCode="DE" term="%22Evaluation+research%22">Evaluation research</searchLink><br /><searchLink fieldCode="DE" term="%22Treatment+effectiveness%22">Treatment effectiveness</searchLink><br /><searchLink fieldCode="DE" term="%22Kaplan-Meier+estimator%22">Kaplan-Meier estimator</searchLink><br /><searchLink fieldCode="DE" term="%22Oropharyngeal+cancer%22">Oropharyngeal cancer</searchLink><br /><searchLink fieldCode="DE" term="%22Disease+complications%22">Disease complications</searchLink>
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: <bold>Background: </bold>Patients with human papillomavirus (HPV)-positive oropharyngeal squamous cell carcinoma have high survival when treated with radiotherapy plus cisplatin. Whether replacement of cisplatin with cetuximab-an antibody against the epidermal growth factor receptor-can preserve high survival and reduce treatment toxicity is unknown. We investigated whether cetuximab would maintain a high proportion of patient survival and reduce acute and late toxicity.<bold>Methods: </bold>RTOG 1016 was a randomised, multicentre, non-inferiority trial at 182 health-care centres in the USA and Canada. Eligibility criteria included histologically confirmed HPV-positive oropharyngeal carcinoma; American Joint Committee on Cancer 7th edition clinical categories T1-T2, N2a-N3 M0 or T3-T4, N0-N3 M0; Zubrod performance status 0 or 1; age at least 18 years; and adequate bone marrow, hepatic, and renal function. We randomly assigned patients (1:1) to receive either radiotherapy plus cetuximab or radiotherapy plus cisplatin. Randomisation was balanced by using randomly permuted blocks, and patients were stratified by T category (T1-T2 vs T3-T4), N category (N0-N2a vs N2b-N3), Zubrod performance status (0 vs 1), and tobacco smoking history (≤10 pack-years vs >10 pack-years). Patients were assigned to receive either intravenous cetuximab at a loading dose of 400 mg/m2 5-7 days before radiotherapy initiation, followed by cetuximab 250 mg/m2 weekly for seven doses (total 2150 mg/m2), or cisplatin 100 mg/m2 on days 1 and 22 of radiotherapy (total 200 mg/m2). All patients received accelerated intensity-modulated radiotherapy delivered at 70 Gy in 35 fractions over 6 weeks at six fractions per week (with two fractions given on one day, at least 6 h apart). The primary endpoint was overall survival, defined as time from randomisation to death from any cause, with non-inferiority margin 1·45. Primary analysis was based on the modified intention-to-treat approach, whereby all patients meeting eligibility criteria are included. This study is registered with ClinicalTrials.gov, number NCT01302834.<bold>Findings: </bold>Between June 9, 2011, and July 31, 2014, 987 patients were enrolled, of whom 849 were randomly assigned to receive radiotherapy plus cetuximab (n=425) or radiotherapy plus cisplatin (n=424). 399 patients assigned to receive cetuximab and 406 patients assigned to receive cisplatin were subsequently eligible. After median follow-up duration of 4·5 years, radiotherapy plus cetuximab did not meet the non-inferiority criteria for overall survival (hazard ratio [HR] 1·45, one-sided 95% upper CI 1·94; p=0·5056 for non-inferiority; one-sided log-rank p=0·0163). Estimated 5-year overall survival was 77·9% (95% CI 73·4-82·5) in the cetuximab group versus 84·6% (80·6-88·6) in the cisplatin group. Progression-free survival was significantly lower in the cetuximab group compared with the cisplatin group (HR 1·72, 95% CI 1·29-2·29; p=0·0002; 5-year progression-free survival 67·3%, 95% CI 62·4-72·2 vs 78·4%, 73·8-83·0), and locoregional failure was significantly higher in the cetuximab group compared with the cisplatin group (HR 2·05, 95% CI 1·35-3·10; 5-year proportions 17·3%, 95% CI 13·7-21·4 vs 9·9%, 6·9-13·6). Proportions of acute moderate to severe toxicity (77·4%, 95% CI 73·0-81·5 vs 81·7%, 77·5-85·3; p=0·1586) and late moderate to severe toxicity (16·5%, 95% CI 12·9-20·7 vs 20·4%, 16·4-24·8; p=0·1904) were similar between the cetuximab and cisplatin groups.<bold>Interpretation: </bold>For patients with HPV-positive oropharyngeal carcinoma, radiotherapy plus cetuximab showed inferior overall survival and progression-free survival compared with radiotherapy plus cisplatin. Radiotherapy plus cisplatin is the standard of care for eligible patients with HPV-positive oropharyngeal carcinoma.<bold>Funding: </bold>National Cancer Institute USA, Eli Lilly, and The Oral Cancer Foundation. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of Lancet is the property of Lancet and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=134093538
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/S0140-6736(18)32779-X
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 11
        StartPage: 40
    Subjects:
      – SubjectFull: Antineoplastic agents
        Type: general
      – SubjectFull: Cisplatin
        Type: general
      – SubjectFull: Comparative studies
        Type: general
      – SubjectFull: Drug administration
        Type: general
      – SubjectFull: Research methodology
        Type: general
      – SubjectFull: Medical cooperation
        Type: general
      – SubjectFull: Papillomavirus diseases
        Type: general
      – SubjectFull: Radiotherapy
        Type: general
      – SubjectFull: Research
        Type: general
      – SubjectFull: Research funding
        Type: general
      – SubjectFull: Evaluation research
        Type: general
      – SubjectFull: Treatment effectiveness
        Type: general
      – SubjectFull: Kaplan-Meier estimator
        Type: general
      – SubjectFull: Oropharyngeal cancer
        Type: general
      – SubjectFull: Disease complications
        Type: general
    Titles:
      – TitleFull: Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Gillison, Maura L.
      – PersonEntity:
          Name:
            NameFull: Ringash, Jolie
      – PersonEntity:
          Name:
            NameFull: Galvin, James
      – PersonEntity:
          Name:
            NameFull: Min Yao
      – PersonEntity:
          Name:
            NameFull: Koyfman, Shlomo A.
      – PersonEntity:
          Name:
            NameFull: Blakaj, Dukagjin M.
      – PersonEntity:
          Name:
            NameFull: Razaq, Mohammed A.
      – PersonEntity:
          Name:
            NameFull: Colevas, A. Dimitrios
      – PersonEntity:
          Name:
            NameFull: Quynh Thu Le
      – PersonEntity:
          Name:
            NameFull: Beitler, Jonathan J.
      – PersonEntity:
          Name:
            NameFull: Jones, Christopher U.
      – PersonEntity:
          Name:
            NameFull: Dunlap, Neal E.
      – PersonEntity:
          Name:
            NameFull: Trotti, Andy M.
      – PersonEntity:
          Name:
            NameFull: Seaward, Samantha A.
      – PersonEntity:
          Name:
            NameFull: Spencer, Sharon
      – PersonEntity:
          Name:
            NameFull: Galloway, Thomas J.
      – PersonEntity:
          Name:
            NameFull: Phan, Jack
      – PersonEntity:
          Name:
            NameFull: Yao, Min
      – PersonEntity:
          Name:
            NameFull: Le, Quynh Thu
      – PersonEntity:
          Name:
            NameFull: Harris, Jonathan
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 05
              M: 01
              Text: 1/5/2019
              Type: published
              Y: 2019
          Identifiers:
            – Type: issn-print
              Value: 01406736
          Numbering:
            – Type: volume
              Value: 393
            – Type: issue
              Value: 10166
          Titles:
            – TitleFull: Lancet
              Type: main
ResultId 1